Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year total asset growth rate
Latest
-6.91%
↓ 132% vs avg
Percentile
P49
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
21.49%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -6.91% |
| Q3 2025 | -1.17% |
| Q2 2025 | -8.62% |
| Q1 2025 | -8.10% |
| Q4 2024 | 53.10% |
| Q3 2024 | -9.10% |
| Q2 2024 | -12.46% |
| Q1 2024 | 489.38% |
| Q4 2023 | -28.28% |
| Q3 2023 | 20.78% |
| Q2 2023 | -33.12% |
| Q1 2023 | 8.60% |
| Q4 2022 | -8.70% |
| Q3 2022 | 13.42% |
| Q2 2022 | -47.94% |
| Q1 2022 | -22.83% |
| Q4 2021 | -15.88% |
| Q3 2021 | 48.80% |
| Q2 2021 | 1.17% |
| Q1 2021 | 44.77% |
| Q4 2020 | -26.07% |
| Q3 2020 | -14.48% |
| Q2 2020 | 56.86% |
| Q1 2020 | 22.18% |
| Q4 2019 | -36.87% |
| Q3 2019 | -4.07% |
| Q2 2019 | -20.37% |
| Q1 2019 | 6.58% |
| Q4 2018 | 3.90% |
| Q3 2018 | 8.80% |
| Q2 2018 | -4.92% |
| Q1 2018 | 51.56% |
| Q4 2017 | 52.90% |
| Q3 2017 | 366.35% |
| Q2 2017 | 69.84% |
| Q1 2017 | -38.28% |
| Q4 2016 | -39.80% |
| Q3 2016 | -27.25% |
| Q2 2016 | -22.20% |
| Q1 2016 | -21.83% |